Cyclerion Therapeutics (NASDAQ:CYCN) Issues Earnings Results

Cyclerion Therapeutics (NASDAQ:CYCN) posted its quarterly earnings data on Tuesday. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($17.20) by $16.44, Zacks reports. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative return on equity of 39.23%.

Cyclerion Therapeutics Stock Performance

Shares of NASDAQ:CYCN traded down $0.01 during midday trading on Tuesday, hitting $3.18. The company’s stock had a trading volume of 55,542 shares, compared to its average volume of 4,212,205. The business’s 50 day simple moving average is $2.55 and its 200 day simple moving average is $1.87. The company has a market cap of $13.77 million, a P/E ratio of -2.74 and a beta of 1.80. Cyclerion Therapeutics has a 12-month low of $1.03 and a 12-month high of $8.48.

Hedge Funds Weigh In On Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP purchased a new position in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned approximately 0.40% of Cyclerion Therapeutics at the end of the most recent quarter. Institutional investors own 75.62% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.